Search
UCB-1184197
go.drugbank.com/drugs/DB05092InvestigationalCDP323 is an antagonist of the _vascular cell adhesion molecule 1_ (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple … (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.
Casdatifan
go.drugbank.com/drugs/DB21701InvestigationalCasdatifan has a monoisotopic molecular weight of 439.09 Da. … Casdatifan is a small molecule drug. The usage of the INN stem '-tifan' in the name indicates that Casdatifan is a hypoxia inducible factor (HIF)-2alpha (HIF-2a) inhibitor.
Flunixin
go.drugbank.com/drugs/DB11518ExperimentalVet approvedFlunixin may be also referred to as _Banamine_, and other trade names. … Flunixin is regulated in the United States by the Food and Drug Administration (FDA) and must be prescribed by a licensed veterinarian.
Frespaciguat
go.drugbank.com/drugs/DB21683InvestigationalFrespaciguat is a small molecule drug. The usage of the INN stem '-ciguat' in the name indicates that Frespaciguat is a guanylate cyclase activator and stimulator. … Frespaciguat has a monoisotopic molecular weight of 608.14 Da.
Crizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigational[T734] Currently, patients are prescribed [hydroxyurea] to raise levels of fetal hemoglobin as a method of reducing morbidity and mortality. … [L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India.
UB-612
go.drugbank.com/drugs/DB16444InvestigationalThe vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the … This vaccine was designed to induce a broad immune response. It was able to reduce viral load and prevent COVID-19 infection in a mouse challenge model and in rhesus macaques[L30653, L30658].
NTx-265
go.drugbank.com/drugs/DB05649InvestigationalNTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause … In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265.
Nizubaglustat
go.drugbank.com/drugs/DB21603InvestigationalNizubaglustat is a small molecule drug. The usage of the INN stem '-glustat' in the name indicates that Nizubaglustat is a ceramide glucosyltransferase inhibitor. … Nizubaglustat has a monoisotopic molecular weight of 433.23 Da.
Synonyms: AZ-3102TRC093
go.drugbank.com/drugs/DB06356InvestigationalTRC093 is a recombinant humanized IgG1k monoclonal antibody.